ClinicalTrials.gg
CompletedNCT07374406Updated Aug 13, 2026

To Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers

A Phase 1 interventional study of Epaminurad 9 mg (JW Pharmaceutical) and Epaminurad 9 mg (Shanghai STA Pharmaceutical) in Healthy, sponsored by JW Pharmaceutical. Completed at 1 site in South Korea. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by JW Pharmaceutical · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Study summary

A randomized, open-label, single dose, 2x2 crossover study to evaluate the safety and pharmacokinetic characteristics after administration of Epaminurad in healthy adult volunteers under fasting conditions

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

JW Pharmaceutical is the lead sponsor of 77 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 19\~55
  2. Weight: at least 50 kg for males and 45 kg for females. (BMI): 18.0 kg/m\^2 or heavier and below 30.0 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  1. Medical history- chronic liver disease, acute gout attack, uric acid stone, diabetes, hypertension, hyperlipidemia or lipid abnormality
  2. Clinical examination- (CKD-EPI) \< 60mL/min/1.73m\^2, (SGOT), ALT (SGPT) > ranges X 2, CK > upper limit of normal ranges X 5, Positive serologic results Cystatin C > 1.26mg/L
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Group 1

    Subjects receive a single dose of Treatment A (JW Pharmaceutical) in Period 1, followed by a washout period, and then a single dose of Treatment B (Shanghai STA Pharmaceutical) in Period 2.

    Drug: Epaminurad 9 mg (JW Pharmaceutical) · Drug: Epaminurad 9 mg (Shanghai STA Pharmaceutical)

  • Experimental
    Group 2

    Subjects receive a single dose of Treatment B (Shanghai STA Pharmaceutical) in Period 1, followed by a washout period, and then a single dose of Treatment A (JW Pharmaceutical) in Period 2.

    Drug: Epaminurad 9 mg (JW Pharmaceutical) · Drug: Epaminurad 9 mg (Shanghai STA Pharmaceutical)

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration versus time curve (AUC)

    To evaluate the AUC of Epaminurad

    Time frame: 3 days

  2. Peak plasma concentrations (Cmax)

    To evaluate the Cmax of Epaminurad

    Time frame: 3 days

07

Study locations

1 site
  • Jeonbuk National University Hospital
    Jeonju, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2026 to primary completion in Feb 2026, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 1, 2026
First posted
Jan 28, 2026
StartActual
Feb 2, 2026
Primary completionActual
Feb 19, 2026
CompletionActual
Feb 24, 2026
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07374406
Lead sponsor
JW Pharmaceutical
Responsible party
Sponsor
First posted
Jan 28, 2026
Start date
Feb 2, 2026
Primary completion
Feb 19, 2026
Completion
Feb 24, 2026
Last update
Aug 13, 2026

Study contacts

Seol Ju Moon
principal investigator · Jeonbuk National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epaminurad

Start the discussion